• Species Reactivity

  Human

• Specificity

  Detects human Serpin E1/PAI‑1 in direct ELISAs.

• Source

  Recombinant Monoclonal Rabbit IgG Clone # 1121C

• Purification

  Protein A or G purified from cell culture supernatant

• Immunogen

  S. frugiperda insect ovarian cell line     Sf 21-derived recombinant human Serpin E1/PAI‑1    
  Met1-Pro402    
  Accession # NP_000593

• Formulation

  Supplied as a solution in PBS containing BSA, Glycerol and Sodium Azide. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.

• Label

  Unconjugated

Applications

• Recommended    
  Concentration

  Sample

• Western Blot

  1:1000 dilution

  See below

• 
  

• Simple Western

  1:100 dilution

  See below

• 
  

Please Note: Optimal dilutions should be determined by each laboratory for each application.  are available in the Technical Information section on our website.

Data Examples

Preparation and Storage

• Shipping

  The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C

• Stability & Storage

  Use a manual defrost freezer and avoid repeated freeze-thaw cycles.    

• 12 months from date of receipt, -20 °C, as supplied.

• 1 month, 2 to 8 °C under sterile conditions after opening.

• 6 months, -20 to -70 °C under sterile conditions after opening.

Background: Serpin E1/PAI-1

As a member of the Serpin superfamily of serine protease inhibitors, Serpin E1/PAI‑1 is the principle inhibitor of urokinase‑type plasminogen activator (uPA) and tissue‑type PA (1, 2). As important regulators of extracellular matrix remodeling, uPA and PAI‑1 play a major role in many processes such as angiogenesis, tumor invasion and obesity (2‑4). For example, uPA and PAI-1 are the only tumor prognostic factors validated at the highest level of evidence with regard to their clinical utility in breast cancer (5). The human PAI-1 is initially synthesized as 402 amino acid precursor with a N‑terminal signal peptide (6, 7). PAI‑1 may exist in one of two possible conformations, designated as active or latent (8). The purified rhPAI‑1 is active against rhuPA. The heterogeneity at the N‑terminus of the purified
rhPAI‑1 has been observed before for both the recombinant and native proteins (9).

• References:

1. Silverman, G.A. et al. (2001) J. Biol. Chem. 276:33293.

2. Stefansson, S. et al. (2003) Curr. Pharm. Des. 9:1545.

3. Duffy, M.J. (2002) Clin. Chem. 48:1194.

4. Juhan-Vague, I. et al. (2003) J. Thromb. Haemost. 1:1575.

5. Harbeck, N. et al. (2002) Clin. Breast Cancer 3:196.

6. Pannekoek, H. et al. (1986) EMBO J. 5:2539.

7. Ginsburg, D. et al. (1986) J. Clin. Invest. 78:1673.

8. Wang, Z. et al. (1996) Biochemistry 35:16443.

9. Stromqvist, M. et al. (1994) Protein Expr. Purif. 5:309.

• Long Name:

  Plasminogen Activator Inhibitor

• Entrez Gene IDs:

  5054 (Human); 18787 (Mouse)

• Alternate Names:

  Endothelial plasminogen activator inhibitor; Nexin; PAI1; PAI-1; PAI1PAI-1; PAISerpin E1; PLANH1; PLANH1plasminogen activator inhibitor 1; serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminogenactivator inhibitor type 1), member 1; Serpin E1; serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitortype 1), member 1